Invert Graphite Limited has released a press release.
Appendix 4C - June 2018 quarter
Filed with ASX ·
6ix hasn’t read this filing yet.
Invert Graphite Limited on 6ix
Earlier from Invert Graphite
- Recruitment complete in VF00102 Phase 2 clinical trial
- Screening to close as clinical trial nears completion
- Clinical Trial Update
- Receipt of $1.23M R&D tax incentive
- Clinical trial update - recruitment enters final phase
Later from Invert Graphite
- Half Yearly Report and Accounts
- Last patient completes treatment in VLU Ph 2 Clinical Trial
- Factor Therapeutics Appoints Transaction Advisor
- Appendix 4C - September 2018 Quarter
- Results of Phase 2 Clinical Trial
Follow Invert Graphite into a list and get an email when it puts out news.
Follow Invert Graphite